PROGYNY INC (PGNY) Stock Fundamental Analysis
NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock - Currency: USD
Taking everything into account, PGNY scores 6 out of 10 in our fundamental rating. PGNY was compared to 103 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making PGNY a very profitable company, without any liquidiy or solvency issues. PGNY is not valued too expensively and it also shows a decent growth rate. This makes PGNY very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
PGNY had a positive operating cash flow in the past year.
Each year in the past 5 years PGNY has been profitable.
Each year in the past 5 years PGNY had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PGNY (7.19%) is better than 89.32% of its industry peers.
PGNY has a Return On Equity of 11.24%. This is in the better half of the industry: PGNY outperforms 75.73% of its industry peers.
PGNY has a Return On Invested Capital of 11.34%. This is amongst the best in the industry. PGNY outperforms 87.38% of its industry peers.
PGNY had an Average Return On Invested Capital over the past 3 years of 8.25%. This is in line with the industry average of 9.71%.
The last Return On Invested Capital (11.34%) for PGNY is above the 3 year average (8.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 11.24% | ||
| ROIC | 11.34% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
1.3 Margins
PGNY has a Profit Margin of 4.33%. This is in the better half of the industry: PGNY outperforms 74.76% of its industry peers.
In the last couple of years the Profit Margin of PGNY has declined.
PGNY has a better Operating Margin (6.03%) than 63.11% of its industry peers.
PGNY's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 21.99%, PGNY perfoms like the industry average, outperforming 45.63% of the companies in the same industry.
PGNY's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.03% | ||
| PM (TTM) | 4.33% | ||
| GM | 21.99% |
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PGNY is still creating some value.
PGNY has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PGNY has been increased compared to 5 years ago.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PGNY has an Altman-Z score of 7.03. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.03, PGNY belongs to the top of the industry, outperforming 89.32% of the companies in the same industry.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.03 |
ROIC/WACC1.26
WACC8.99%
2.3 Liquidity
A Current Ratio of 2.39 indicates that PGNY has no problem at all paying its short term obligations.
The Current ratio of PGNY (2.39) is better than 83.50% of its industry peers.
PGNY has a Quick Ratio of 2.39. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY's Quick ratio of 2.39 is amongst the best of the industry. PGNY outperforms 84.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.39 |
3. Growth
3.1 Past
PGNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.56%.
PGNY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -4.77% yearly.
PGNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.46%.
PGNY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.42% yearly.
EPS 1Y (TTM)-6.56%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)9.46%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%16.53%
3.2 Future
The Earnings Per Share is expected to grow by 31.89% on average over the next years. This is a very strong growth
Based on estimates for the next years, PGNY will show a quite strong growth in Revenue. The Revenue will grow by 9.02% on average per year.
EPS Next Y-3.41%
EPS Next 2Y28.77%
EPS Next 3Y24.64%
EPS Next 5Y31.89%
Revenue Next Year6.75%
Revenue Next 2Y9.11%
Revenue Next 3Y10.46%
Revenue Next 5Y9.02%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 37.65, which means the current valuation is very expensive for PGNY.
The rest of the industry has a similar Price/Earnings ratio as PGNY.
The average S&P500 Price/Earnings ratio is at 27.45. PGNY is valued slightly more expensive when compared to this.
The Price/Forward Earnings ratio is 22.70, which indicates a rather expensive current valuation of PGNY.
PGNY's Price/Forward Earnings is on the same level as the industry average.
PGNY is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.90, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.65 | ||
| Fwd PE | 22.7 |
4.2 Price Multiples
PGNY's Enterprise Value to EBITDA is on the same level as the industry average.
PGNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PGNY is cheaper than 87.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.4 | ||
| EV/EBITDA | 18.74 |
4.3 Compensation for Growth
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PGNY's earnings are expected to grow with 24.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y24.64%
5. Dividend
5.1 Amount
No dividends for PGNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.46
+0.22 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.2%
Inst Owner Change-8.73%
Ins Owners1.37%
Ins Owner Change1.64%
Market Cap1.84B
Analysts77.5
Price Target27.25 (26.98%)
Short Float %8.36%
Short Ratio6.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.62%
Min EPS beat(2)-11.77%
Max EPS beat(2)15%
EPS beat(4)1
Avg EPS beat(4)-4.37%
Min EPS beat(4)-19.12%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)12.82%
EPS beat(12)9
Avg EPS beat(12)54.88%
EPS beat(16)13
Avg EPS beat(16)111.04%
Revenue beat(2)2
Avg Revenue beat(2)4.47%
Min Revenue beat(2)3.19%
Max Revenue beat(2)5.74%
Revenue beat(4)2
Avg Revenue beat(4)0.3%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)7
Avg Revenue beat(12)0.33%
Revenue beat(16)7
Avg Revenue beat(16)-0.81%
PT rev (1m)-2.09%
PT rev (3m)-1.67%
EPS NQ rev (1m)-13.51%
EPS NQ rev (3m)-12.98%
EPS NY rev (1m)-7.61%
EPS NY rev (3m)-4.64%
Revenue NQ rev (1m)0.62%
Revenue NQ rev (3m)2.69%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)2.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.65 | ||
| Fwd PE | 22.7 | ||
| P/S | 1.52 | ||
| P/FCF | 9.4 | ||
| P/OCF | 9.05 | ||
| P/B | 3.94 | ||
| P/tB | 4.17 | ||
| EV/EBITDA | 18.74 |
EPS(TTM)0.57
EY2.66%
EPS(NY)0.95
Fwd EY4.4%
FCF(TTM)2.28
FCFY10.64%
OCF(TTM)2.37
OCFY11.05%
SpS14.15
BVpS5.45
TBVpS5.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 11.24% | ||
| ROCE | 14.82% | ||
| ROIC | 11.34% | ||
| ROICexc | 23.6% | ||
| ROICexgc | 26.56% | ||
| OM | 6.03% | ||
| PM (TTM) | 4.33% | ||
| GM | 21.99% | ||
| FCFM | 16.14% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score7
Asset Turnover1.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 207.4% | ||
| Cap/Sales | 0.61% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 265.01% | ||
| Profit Quality | 372.94% | ||
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.39 | ||
| Altman-Z | 7.03 |
F-Score7
WACC8.99%
ROIC/WACC1.26
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.56%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-3.41%
EPS Next 2Y28.77%
EPS Next 3Y24.64%
EPS Next 5Y31.89%
Revenue 1Y (TTM)9.46%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%16.53%
Revenue Next Year6.75%
Revenue Next 2Y9.11%
Revenue Next 3Y10.46%
Revenue Next 5Y9.02%
EBIT growth 1Y11.23%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year26.8%
EBIT Next 3Y17.86%
EBIT Next 5Y15.2%
FCF growth 1Y79.62%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y80.28%
OCF growth 3Y90.18%
OCF growth 5YN/A